Incorporating a polygenic risk score into prostate cancer screening could enhance the detection of clinically significant prostate cancer that conventional screening may miss, according to results of ...

A polygenic risk score was able to detect a high proportion of clinically significant prostate cancer. Cancer would not have been detected in 71.8% of patients with the use of PSA or MRI screening.

A retrospective study found that the 313-SNP breast cancer polygenic risk score (PRS 313) blood test could predict future incidents of breast cancer in women diagnosed with ductal carcinoma in situ ...

“What makes the score so powerful is its ability to predict, before the age of five, whether a child is likely to develop obesity in adulthood, well before other risk factors start to shape their ...

Nearly all men with a polygenic risk score in the 90th percentile or above had a 10-year absolute risk for prostate cancer exceeding 3.8%. A polygenic risk score (PRS) identifies more patients with ...

Combining a polygenic risk score (PRS) with traditional biomarkers can help clinicians better estimate a patient’s risk of developing coronary artery disease (CAD), according to new UK Biobank data.

A polygenic risk score (PRS) may help identify women who are at a greater risk of developing a future breast cancer after treatment for in situ breast disease, a retrospective study suggests. The ...

Cardiovascular disease ("CVD") is the leading cause of death in the US and worldwide with over 82 million Americans living with CVD. CVD accounts for one in every three deaths in the US, or more than ...

Millions struggle with depression and anxiety, often enduring long waits for effective treatment. Scientists in Sweden, Denmark, and Germany are developing a genetic test to predict which medications ...

Cost-utility studies provide critical information for the costs and benefits of using any new test, typically building on existing public health and screening programmes, within a defined population.